SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare - Quaterly Results

07 Feb 2026 Evaluate
A decent increase of about 32.15% in the sales to Rs. 1657.05 millions was observed for the quarter ended December 2025. The sales figure stood at Rs. 1253.87 millions during the year-ago period.A meek growth of 1.83% was reported for the quarter ended December 2025 to Rs. 159.34  millions from Rs. 156.48 millions.Operating profit for the quarter ended December 2025 rose to 422.95 millions as compared to 387.31 millions of corresponding quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 1657.05 1253.87 32.15 3930.71 3511.88 11.93 4773.42 3097.87 54.09
Other Income 112.88 162.60 -30.58 460.21 685.03 -32.82 838.34 891.16 -5.93
PBIDT 422.95 387.31 9.20 1331.69 1571.31 -15.25 2084.35 1154.08 80.61
Interest 27.43 11.92 130.12 74.20 39.65 87.14 66.04 172.57 -61.73
PBDT 373.49 370.53 0.80 1168.00 1517.49 -23.03 1560.93 877.00 77.99
Depreciation 135.64 121.95 11.23 393.07 365.17 7.64 488.56 496.11 -1.52
PBT 237.85 248.58 -4.32 774.93 1152.32 -32.75 1072.37 380.89 181.54
TAX 78.51 92.10 -14.76 100.34 417.10 -75.94 374.35 111.52 235.68
Deferred Tax 65.57 0.00 0.00 123.94 6.50 1806.77 -96.43 -1.35 7042.96
PAT 159.34 156.48 1.83 674.59 735.22 -8.25 698.02 269.37 159.13
Equity 195.58 97.79 100.00 195.58 97.79 100.00 97.79 86.80 12.66
PBIDTM(%) 25.52 30.89 -17.37 33.88 44.74 -24.28 43.67 37.25 17.21

Shilpa Medicare Share Price

441.05 4.80 (1.10%)
11-May-2026 10:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1863.90
Dr. Reddys Lab 1279.75
Cipla 1338.65
Zydus Lifesciences 935.55
Lupin 2250.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×